NASDAQ:CVRX - Nasdaq - US1266381052 - Common Stock - Currency: USD
13.85
-0.16 (-1.14%)
The current stock price of CVRX is 13.85 USD. In the past month the price decreased by -23.61%. In the past year, price decreased by -37.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 200 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
CVRX INC
9201 West Broadway Avenue, Suite 650
Minneapolis MINNESOTA US
CEO: Nadim Yared
Employees: 200
Company Website: https://www.cvrx.com/
Investor Relations: https://ir.cvrx.com/
Phone: 17634162850
The current stock price of CVRX is 13.85 USD. The price decreased by -1.14% in the last trading session.
The exchange symbol of CVRX INC is CVRX and it is listed on the Nasdaq exchange.
CVRX stock is listed on the Nasdaq exchange.
13 analysts have analysed CVRX and the average price target is 21.22 USD. This implies a price increase of 53.18% is expected in the next year compared to the current price of 13.85. Check the CVRX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CVRX INC (CVRX) has a market capitalization of 350.68M USD. This makes CVRX a Small Cap stock.
CVRX INC (CVRX) currently has 200 employees.
CVRX INC (CVRX) has a support level at 13.84 and a resistance level at 14.35. Check the full technical report for a detailed analysis of CVRX support and resistance levels.
The Revenue of CVRX INC (CVRX) is expected to grow by 25.67% in the next year. Check the estimates tab for more information on the CVRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CVRX does not pay a dividend.
CVRX INC (CVRX) will report earnings on 2025-04-28, after the market close.
CVRX INC (CVRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.69).
The outstanding short interest for CVRX INC (CVRX) is 7.98% of its float. Check the ownership tab for more information on the CVRX short interest.
ChartMill assigns a technical rating of 2 / 10 to CVRX. When comparing the yearly performance of all stocks, CVRX is a bad performer in the overall market: 86.34% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to CVRX. CVRX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CVRX reported a non-GAAP Earnings per Share(EPS) of -2.69. The EPS decreased by -35.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.8% | ||
ROE | -89.71% | ||
Debt/Equity | 0.76 |
ChartMill assigns a Buy % Consensus number of 82% to CVRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 24.22% and a revenue growth 25.67% for CVRX